avita medical reports strong half year financi, page-5

No worries, keepsmiling -strange that it didn't appear up as a HC notice.



Some parts that stood out for me;




ReCell is being adopted by key surgeons in a wide range of indications and is becoming the preferred first line approach for the treatment of many chronic and acute wounds, plastic and reconstructive surgeries and an expanding range of aesthetics procedures



We maintain our strong commitment to improved efficiencies and are extracting further gains in gross margins for our products”



Avita has commenced development work on the ‘Next Generation’ regenerative product"s" ...



We currently have five studies underway throughout Europe on indications including chronic leg ulcers, acne scars &
wrinkles, vitiligo and treatment of donor sites following skin grafting.




Even with the expected increase in R&D and marketing expenditure, it's reassuring to know we still have 10.8 million dollars still in the bank.